In a regulatory filing, Eiger BioPharmaceuticals disclosed that its director Jeffrey Glenn bought 100K shares of common stock on December 22nd in a total transaction size of $128K.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EIGR:
- Eiger BioPharmaceuticals CEO David Cory resigns, David Apelian named Interim CEO
- Biotech Alert: Searches spiking for these stocks today
- Eiger BioPharmaceuticals price target lowered to $9 from $48 at BTIG
- Eiger BioPharmaceuticals price target lowered to $3 from $29 at Baird
- Eiger BioPharmaceuticals price target lowered to $4 from $23 at Citi
